Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection

Zemskova, Marina; Marinets, Maria V; Сивков, А.В.; Pavlova, Yu V; Shibaev, A N; Sorokin, Konstantin S

doi:10.3389/fonc.2020.610647

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lately ITGαV was suggested as a novel non-invasive marker for PC detection, since significantly lower levels were found in patients with PC compared to healthy controls (40). However, this analysis could not find significant ITGαV expression differences in patients with localized PC.…”

Section: Itg Expression In the Mskcc (A-b) And Tcga (C-e) Cohort For ...mentioning

confidence: 57%

Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based ExploratoryIn SilicoAnalysis

Neuberger¹,

Frey²,

Nitschke³

et al. 2022

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Diagnostic and prognostic biomarkers in localized prostate cancer (PC) are insufficient. Treatment stratification relies on prostate-specific antigen, clinical tumor staging and International Society of Urological Pathology (ISUP) grading, whereas molecular profiling remains unused. Integrins (ITG) have an important function in bidirectional signaling and are associated with progression, proliferation, perineural invasion, angiogenesis, metastasis, neuroendocrine differentiation, and a more aggressive disease phenotype in PC. However, ITG subunit expression in localized PC and their utility as prognostic biomarkers has not yet been analyzed. This study aimed to fill this gap and provide a comprehensive overview of ITG expression as well as ITG utility as biomarkers. Patients and Methods: The Cancer Genome Atlas (TCGA) and the Memorial Sloan Kettering Cancer Center (MSKCC) prostate adenocarcinoma cohorts were analyzed regarding ITG expression in correlation to ISUP, N-and American Joint Committee on Cancer (AJCC) stage and were correlated with disease-free survival (DFS). Statistical tests used included the Mann-Whitney U-test, logrank test and uni-and multivariable cox regression analyses. Results: After grouping for ISUP (1 and 2 vs. 3-5), N0 vs. N1 and AJCC stage (≤2 vs. ≥3), multiple ITGs showed significant expression differences. The most consistent results were observed for ITGα4, ITGαX, ITGα11, ITGβ2 and ITGα2. In multivariable cox regression, ITGα2, ITGα10, ITGαD, ITGαB2 (TCGA), ITGα11 and ITGβ4 (MSKCC) were independent predictors of DFS. Conclusion: The utility of ITGs as PC biomarkers was herein shown.Prostate cancer (PC) is the second most common cancer in men and ranks fifth in cancer-related mortality worldwide (1). The introduction of prostate-specific antigen (PSA) screening led to a significant reduction of mortality over the last decades. Next to PSA, current PC screening and treatment decision/stratification is based on digital rectal examination (DRE) and prostate biopsy with or without magnetic resonance imaging (MRI) guidance (2). However, there are several limitations in detection and risk stratification. PSA is organ-, but not tumor-specific. This explains why PC detection biopsy is only positive in around 25% for patients with PSA 2-10 ng/ml (3). False-positive results above thresholds (e.g., in patients with benign prostatic hyperplasia or prostatitis) limit the accuracy. Another critique on the use of PSA screening in PC detection is overdiagnosis and subsequently overtreatment of patients, in which an insignificant PC would never surface during the patient lifespan (3). Additionally, biopsy undersampling may lead to underestimation of the true tumor grade and upgrading after radical prostatectomy (RP) (4-6). Once diagnosed, PC shows an enormous biological heterogeneity: Even though some patients die of metastatic disease within a few years, others can live for 10-20 years with an organ-confined disease (7). This might be due to genomic diversity-like differences in the tr...

show abstract

Section: Itg Expression In the Mskcc (A-b) And Tcga (C-e) Cohort For ...mentioning

confidence: 57%

Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based ExploratoryIn SilicoAnalysis

Neuberger¹,

Frey²,

Nitschke³

et al. 2022

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Due to these facts, screening model for the disease, as well as marker for aggressive forms is needed. Currently, widely used diagnostic and prognostic biomarker PSA show low specificity leading to possible missed diagnosis, and on the other hand, to over-diagnosis of indolent forms of the tumor [ 19 , 20 ]. Furthermore, PSA cannot discriminate between biologically indolent and aggressive cancer type.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, PSA cannot discriminate between biologically indolent and aggressive cancer type. Diagnostic biomarker with better performances, reducing unnecessary prostate biopsies, and recognizing clinically significant tumor is subject of scientific community effort [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…After thawing, seminal plasma was centrifuged at 20,000 g for 10 min. Blood plasma cfDNA was isolated with the NucleoSnap cfDNA kit (from blood plasma and seminal plasma > 1 ml) and Nucleospin (seminal plasma < 1 ml) (MACHERY-NAGEL, Germany) using QIAvac 24 Plus vacuum station (QIAGEN, Germany) as previously published [ 19 ]. Isolated cfDNA was quantified by qPCR on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories) using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories) and primers for 82–bp LINE-1 fragment as previously published [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Methylation pattern of Caveolin-1 in prostate cancer as potential cfDNA biomarker

Škara

Vodopić

Pezelj³

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

High prevalence and mortality of prostate cancer (PCa) are well known global health issues. Novel biomarkers for better identifying patients with PCa are the subject of extensive research. Prostate specific antigen (PSA) shows low specificity in screening and diagnostics, leading to unnecessary biopsies and health costs. Eighty patients with PCa and benign prostate hyperplasia (BPH) were included in the study. We analyzed CAV1 gene expression and methylation in tissue. CAV1 cfDNA methylation from blood and seminal plasma was accessed as a potential PCa biomarker. Although methylation in blood plasma did not differ between PCa and BPH patients, methylation in seminal plasma showed better PCa biomarker performances than tPSA (AUC 0.63 vs. AUC 0.52). Discrimination of BPH and Gleason grade group 1 PCa patients from patients with higher Gleason grade groups revealed very good performance as well (AUC 0.72). CAV1 methylation is useful biomarker with potential for further seminal plasma cfDNA research, but its diagnostic accuracy should be improved, as well as general knowledge about cfDNA in seminal plasma.

show abstract

Recent advancements in polyaniline-based biosensors for diagnosis of cancers: A comprehensive review

Hosseine,

Bakhshi,

Naghib

et al. 2024

TrAC Trends in Analytical Chemistry

View full text Add to dashboard Cite

Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection

Cited by 7 publications

References 30 publications

Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based ExploratoryIn SilicoAnalysis

Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based ExploratoryIn SilicoAnalysis

Methylation pattern of Caveolin-1 in prostate cancer as potential cfDNA biomarker

Recent advancements in polyaniline-based biosensors for diagnosis of cancers: A comprehensive review

Contact Info

Product

Resources

About